84348-38-9

Basic information

• Product Name: (S)-4-METHYLENE-PYRROLIDINE-1,2-DICARBOXYLIC ACID 1-TERT-BUTYL ESTER
• Synonyms: 1,2-Pyrrolidinedicarboxylicacid, 4-Methylene-, 1-(1,1-diMethylethyl) ester, (2S)-;(S)-1-(tert-butoxycarbonyl)-4-Methylenepyrrolidine-2-carboxylic acid;N-tert-Butoxycarbonyl-4-methylene-L-proline;N-Boc-4-methylene-L-proline 97%;N-T-BOC-4-METHYLENE-L-PROLINE;(S)-4-METHYLENE-PYRROLIDINE-1,2-DICARBOXYLIC ACID 1-TERT-BUTYL ESTER;BOC-4-METHYLENE-L-PROLINE;N-Boc-4-methylene-L-proline
• CAS NO: 84348-38-9
• Molecular Formula: C₁₁H₁₇NO₄
• Molecular Weight: 227.26
• Product Categories: Heterocycles;pharmacetical
• Mol File: 84348-38-9.mol
• Article Data: 14

Chemical Properties

• Melting Point: 110-114°C
• Boiling Point: 349.859 °C at 760 mmHg
• Flash Point: 165.389 °C
• Appearance: /
• Density: 1.18±0.1 g/cm3 (20 ºC 760 Torr)
• Vapor Pressure: 0mmHg at 25°C
• Refractive Index: 1.513
• Storage Temp.: 2-8°C(protect from light)
• PKA: 3.80±0.20(Predicted)
• Water Solubility: Insoluble in water.
• CAS DataBase Reference: (S)-4-METHYLENE-PYRROLIDINE-1,2-DICARBOXYLIC ACID 1-TERT-BUTYL ESTER(CAS DataBase Reference)
• NIST Chemistry Reference: (S)-4-METHYLENE-PYRROLIDINE-1,2-DICARBOXYLIC ACID 1-TERT-BUTYL ESTER(84348-38-9)
• EPA Substance Registry System: (S)-4-METHYLENE-PYRROLIDINE-1,2-DICARBOXYLIC ACID 1-TERT-BUTYL ESTER(84348-38-9)

Safety Data

• Hazard Codes: Xi
• Statements: 36/37/38
• Safety Statements: 26
• WGK Germany: 3
• Hazardous Substances Data: 84348-38-9(Hazardous Substances Data)

Usage

Uses

As important intermediates in various areas such as peptide synthesis, asymmetric synthesis, medicinal chemistry, and polymer chemistry. The fluorous prolins were synthesized from commercially available N-Boc-4-methylene- L-proline.

InChI:InChI=1/C11H17NO4/c1-7-5-8(9(13)14)12(6-7)10(15)16-11(2,3)4/h8H,1,5-6H2,2-4H3,(H,13,14)/t8-/m0/s1

Upstream product

• 15761-39-4 1-(tert-butoxycarbonyl)-L-proline 
• 27200-84-6 methyl triphenylphosphonium bromide 
• 24424-99-5 di-tert-butyl dicarbonate 
• 20309-87-9 (2S)-4-methylenepyrrolidine-2-carboxylic acid 
• 84348-39-0 (S)-1-tert-butyl 2-methyl 4-methylenepyrrolidine-1,2-dicarboxylate 
• 144422-81-1 N-phenylsulphonyl-4-exomethylene-(S)-proline benzylester 
• 144422-80-0 N-phenylsulphonyl-N-propargyl-3-bromo-(S)-alanine benzylester 
• 144423-03-0 N-phenylsulphonyl-N-propargyl-O-tetrahydropyranyl-(S)-serine benzylester 
• 1779-49-3 Methyltriphenylphosphonium bromide 
• 84348-37-8 N-tert-butoxycarbonyl-4-oxo-L-proline 
• 163190-46-3 tert-Butyl (2S)-N-tert-butoxycarbonyl-4-methylideneprolinate 

Downstream Products

• 84348-39-0 (S)-1-tert-butyl 2-methyl 4-methylenepyrrolidine-1,2-dicarboxylate 
• 144422-82-2 N-Boc-4-exomethylene-(S)-prolinyl dibenzyl-(S)-aspartate 
• 20309-87-9 (2S)-4-methylenepyrrolidine-2-carboxylic acid 
• 453524-76-0 (5S,8S)-3-(4-methoxyphenyl)-1-oxa-2,7-diazaspiro[4.4]non-2-ene-7-N-Boc-8-carboxylic acid 
• 453524-72-6 (5R,8S)-3-(2-methoxyphenyl)-1-oxa-2,7-diazaspiro[4.4]non-2-ene-7-N-Boc-8-carboxylic acid 
• 453524-68-0 tert-butyl (5R,8S)-3-(4-methoxyphenyl)-1-oxa-2,7-diazaspiro[4.4]non-2-ene-7-N-Boc-8-carboxylate 
• 453524-69-1 tert-butyl (5S,8S)-3-(4-methoxyphenyl)-1-oxa-2,7-diazaspiro[4.4]non-2-ene-7-N-Boc-8-carboxylate 
• 453524-66-8 tert-butyl (5R,8S)-3-(2-methoxyphenyl)-1-oxa-2,7-diazaspiro[4.4]non-2-ene-7-N-Boc-8-carboxylate 
• 453524-67-9 tert-butyl (5S,8S)-3-(2-methoxyphenyl)-1-oxa-2,7-diazaspiro[4.4]non-2-ene-7-N-Boc-8-carboxylate 
• 453524-71-5 (5S,8S)-3-(2,6-dichlorophenyl)-1-oxa-2,7-diazaspiro[4.4]non-2-ene-7-N-Boc-8-carboxylic acid 
• 453524-63-5 tert-butyl (5S,8S)-3-(2,6-dichlorophenyl)-1-oxa-2,7-diazaspiro[4.4]non-2-ene-7-N-Boc-8-carboxylate 

Relevant articles and documents

MASP INHIBITORY COMPOUNDS AND USES THEREOF

The present invention relates to novel Mannose-binding lectin (MBL)-associated serine protease (MASP) inhibitory compounds, as well as analogues and derivatives thereof, to processes for the preparation thereof, to the use thereof alone or in combinations for treatment and/or prevention of diseases and to the use thereof for production of medicaments for treatment and/or prevention of diseases, especially for treatment and/or prevention of renal and cardiovascular disorders and of ischemia reperfusion injuries.

Ledipasvir preparation method

The invention discloses a Ledipasvir preparation method. The Ledipasvir preparation method includes steps: (1) Ledipasvir intermediate product 1-LD-B preparation; (2) Ledipasvir intermediate product 2-LD-E preparation; (3) Ledipasvir intermediate product 3-LD-F preparation; (4) Ledipasvir intermediate product 4-LD-J preparation; (5) Ledipasvir intermediate product 5-LD-L preparation; (6) Ledipasvir-LD-Q preparation. The Ledipasvir preparation method has advantages of technical maturity and stability, product quality stability, safety and reliability in production process and suitableness for industrial production.

DIHYDROPYRIMIDINE COMPOUNDS AND THEIR APPLICATION IN PHARMACEUTICALS

Provided herein are dihydropyrimidine compounds and their pharmaceutical applications, especially for use in treating and preventing HBV diseases. Specifically, provided herein are compounds having Formula (I) or (Ia), or an enantiomer, a diastereoisomer,